A New Scanner Could Spare Many Women The Trauma Of A Breast Biopsy

April 28, 1999

MAMMOGRAMS reveal lumps in breasts but only a painful biopsy can prove if a lump is benign or cancerous. Now, however, a new device from the US could avoid the need for many biopsies.

Approved for use by the Food and Drug Administration last week, the T-Scan 2000 from TransScan Medical of Ramsey, New Jersey, detects tumours by passing a tiny electric current through the body and measuring the differences in resistance between normal and tumour tissue.

"We want to use the T-Scan to prove there is no cancer. What we're saying is: do the biopsy to prove there is disease," says George Solomon, chief executive officer of TransScan. The results of a mammogram-a low-dose X-ray-are often difficult to interpret. To be safe, doctors perform biopsies, removing tissue from the breast to see if it is cancerous.

Every year in the US, 25 million women have mammograms and about 800 000 have biopsies after results reveal suspect tissue. But only 180 000 actually have breast cancer. TransScan claims the T-Scan could find 6000 cases of cancer that would otherwise go undetected, and spare more than 600 000 women the pain of a biopsy.

The device consists of a hand-held probe that contains a small matrix of sensing electrodes. This is gently placed on the breast above the suspect region, and a wire is attached to the patient's hand to complete the circuit. An alternating current of 1 volt is then passed through the body.

Differences in structure between tumour tissue and normal tissue make tumours about 40 times more conductive than regular tissue. The probes detect these differences as the device is passed over the breast, and a computer generates an image that can then be interpreted by a technician.

"The T-Scan device has the potential to reduce the number of negative biopsies, thus saving women worry about breast lesions that turn out to be noncancerous. It also has the potential to increase the identification of women who should be referred for early biopsy," the FDA said.

Other researchers are working on related techniques. The National Institutes of Health near Washington DC is developing an instrument that maps conductivity variations by passing an oscillating current through the body in a strong magnetic field, which creates detectable ultrasonic vibrations (This Week, 16 January 1999, p 9).
Author: Kurt Kleiner, Washington DC
New Scientist issue 1 May 1999


New Scientist

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.